Vaccine play Iliad draws nine-digit B round; Denmark’s Gubra launches venture creation unit

In a week in which FDA refused to file an application seeking approval of a Moderna vaccine, it’s notable that the largest venture funding went to a vaccine play.

RA Capital Management led the round — a $115 million series B — for  Iliad Biotechnologies Inc., a Weston, Fla.-based company developing an intranasal vaccine for Bortedella pertussis infection. Janus Henderson and BNP Paribas Asset Management Alts joined the round as new investors...